In a report released yesterday, David Novak from Raymond James maintained a Buy rating on Ziopharm Oncology (ZIOP), with a price target of $4.00. The company’s shares closed last Thursday at $2.99.
According to TipRanks.com, Novak is a 1-star analyst with an average return of 0.1% and a 30.5% success rate. Novak covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Knight Therapeutics, and Leap Therapeutics.
Ziopharm Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.95 and a one-year low of $2.06. Currently, Ziopharm Oncology has an average volume of 2.18M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
